Coagulation Screening Reflexive Evaluation
Use
Screening to support and direct the diagnosis of coagulation disorders
Special Instructions
Not provided.
Limitations
This test is subject to limitations such as potential interference from anticoagulant therapies. It is critical for patients to ideally not be on anticoagulant therapy prior to the test. Warfarin should be avoided for two weeks, and heparin, direct Xa, and thrombin inhibitor therapies should be avoided for three days prior to testing to minimize potential interferences that could affect the test’s diagnostic accuracy.
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 98125-8 - Intravascular coag + fibrinolysis Pnl
- 5902-2 - Prothrombin time
- 6301-6 - INR PPP
- 14979-9 - aPTT PPP
- 3243-3 - Thrombin time
- 6303-2 - dRVVT PPP
- 57838-5 - Confirm dRVVT
- 50410-0 - dRVVT screen to confirm ratio
- 3282-1 - aPTT Hex PL PPP
- 21026-0 - Path Interp Bld-Imp
Result Turnaround Time
3-10 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
2.0 mL
Minimum Volume
Not provided
Container
Light blue-top (sodium citrate) collection tubes
Collection Instructions
Plasma must be separated from cells within 45 minutes of venipuncture, and centrifuged a second time before being placed in plastic transport tubes. Freeze plasma within two hours and keep frozen until testing is performed.
Patient Preparation
Ideally, the patient should not be on anticoagulant therapy. Avoid warfarin (Coumadin®) therapy for two weeks prior to testing. Avoid heparin, direct Xa and thrombin inhibitor therapies for three days prior to testing.
Storage Instructions
Freeze.
Other tests from different labs that may be relevant